{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T18:32:33Z","timestamp":1769625153958,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Health Syst."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Post-approval observational studies that rely on traditional data collection approaches may be burdensome for community oncology settings with limited research infrastructure. We conducted a prospective observational study using an EHR-integrated platform to evaluate its feasibility for streamlining data collection in community oncology. We were able to capture high-quality data on infusion-related reactions in patients with multiple myeloma receiving daratumumab. The EHR-integrated platform included centralized patient identification, automated EHR-to-electronic data capture system data transfer, and centralized abstraction services. Over 11 months, 82 patients enrolled at four US community oncology sites, with 30.5% identifying as Black or Hispanic. Across 4568 essential data points: missingness accounted for 0.59%, 91% of data points were eligible for automated transfer, median transfer time for structured data was 1.7 days, and query frequency was &lt;2% with a median resolution time of 5.1 days. This pilot study demonstrated that EHR-integrated platforms can be operationalized in community oncology settings with high data completeness and rapid, diverse enrollment, expanding access to clinical trials outside traditional research centers and producing more generalizable results.<\/jats:p>","DOI":"10.1038\/s44401-025-00066-9","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:00:52Z","timestamp":1769576452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility assessment of an EHR-integrated research platform for prospective data collection in community oncology practice"],"prefix":"10.1038","volume":"3","author":[{"given":"Majd T.","family":"Ghanim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Dykas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Borgsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Dabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmikanth","family":"Katragadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Rodriguez-Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Salcuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Salituro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Zuniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal J.","family":"Meropol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashita S.","family":"Batavia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"66_CR1","unstructured":"U. S. Food and Drug Administration. Postmarketing requirements and commitments: introduction. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/postmarketing-requirements-and-commitments-introduction (2024)."},{"key":"66_CR2","doi-asserted-by":"crossref","unstructured":"Berger, M. et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health 20, (2017).","DOI":"10.1016\/j.jval.2017.07.013"},{"key":"66_CR3","doi-asserted-by":"crossref","unstructured":"Roberts, M. & Ferguson, G. Real-world evidence: bridging gaps in evidence to guide payer decisions. PharmacoEconomics Open 5, 3\u201311 (2020).","DOI":"10.1007\/s41669-020-00221-y"},{"key":"66_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jama.2017.9415","volume":"318","author":"H Naci","year":"2017","unstructured":"Naci, H., Smalley, K. R. & Kesselheim, A. S. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 318, 626\u2013636 (2017).","journal-title":"JAMA"},{"key":"66_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/1078-0432.CCR-23-2268","volume":"30","author":"G Collins","year":"2024","unstructured":"Collins, G., McKelvey, B., Andrews, H. S., Allen, J. D. & Stewart, M. D. An analysis of dosing-related postmarketing requirements for novel oncology drugs approved by the U.S. Food and Drug Administration, 2012-2022. Clin. Cancer Res. 30, 937\u2013941 (2024).","journal-title":"Clin. Cancer Res."},{"key":"66_CR6","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","volume":"23","author":"BA Feinberg","year":"2020","unstructured":"Feinberg, B. A. et al. Use of real-world evidence to support FDA approval of oncology drugs. Value Health 23, 1358\u20131365 (2020).","journal-title":"Value Health"},{"key":"66_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40264-022-01152-9","volume":"45","author":"O Moneer","year":"2022","unstructured":"Moneer, O. et al. New drug postmarketing requirements and commitments in the US: a systematic review of the evidence. Drug Saf. 45, 305\u2013318 (2022).","journal-title":"Drug Saf."},{"key":"66_CR8","doi-asserted-by":"publisher","first-page":"100939","DOI":"10.1016\/j.conctc.2022.100939","volume":"28","author":"G Kumar","year":"2022","unstructured":"Kumar, G., Chaudhary, P., Quinn, A. & Su, D. Barriers for cancer clinical trial enrollment: a qualitative study of the perspectives of healthcare providers. Contemp. Clin. Trials Commun. 28, 100939 (2022).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"66_CR9","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine. Improving Representation in Clinical Trials and Research (The National Academies Press, Washington, DC, 2022). https:\/\/doi.org\/10.17226\/26479.","DOI":"10.17226\/26479"},{"key":"66_CR10","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1200\/JOP.19.00662","volume":"16","author":"AR Wong","year":"2020","unstructured":"Wong, A. R. et al. Barriers to participation in therapeutic clinical trials as perceived by community oncologists. JCO Oncol. Pract. 16, e849\u2013e858 (2020).","journal-title":"JCO Oncol. Pract."},{"key":"66_CR11","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cncr.32755","volume":"126","author":"SJ Niranjan","year":"2020","unstructured":"Niranjan, S. J. et al. Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials. Cancer 126, 1958\u20131968 (2020).","journal-title":"Cancer"},{"key":"66_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/cncr.35145","volume":"130","author":"RD Harvey","year":"2024","unstructured":"Harvey, R. D. et al. A call to action to advance patient-focused and decentralized clinical trials. Cancer 130, 1193\u20131203 (2024).","journal-title":"Cancer"},{"key":"66_CR13","doi-asserted-by":"publisher","first-page":"pkae060","DOI":"10.1093\/jncics\/pkae060","volume":"8","author":"I Altomare","year":"2024","unstructured":"Altomare, I. et al. Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics. JNCI Cancer Spectr. 8, pkae060 (2024).","journal-title":"JNCI Cancer Spectr."},{"key":"66_CR14","unstructured":"Salcuni, P. Optimizing data collection: assessing EHR-to-EDC data transfer potential across structured and unstructured data. AMIA Informatics Summit Proceedings https:\/\/knowledge.amia.org\/ (2025)."},{"key":"66_CR15","doi-asserted-by":"publisher","unstructured":"Rodrigues, J. J. P. C., Compte, S. S. & Diez, I. de la T. Advances on Sensors for Health Systems. in (eds. Rodrigues\u201d, [\u201cJoel Jos\u00e9 P.C., Compte\u201d, \u201cSandra Sendra & Diez\u201d], \u201cIsabel de la Torra) 21\u201331 (Elsevier, 2016) https:\/\/doi.org\/10.1016\/bf978-1-78548-091-1.50002-6.","DOI":"10.1016\/bf978-1-78548-091-1.50002-6"},{"key":"66_CR16","unstructured":"HL7 International. HL7 FHIR. ROHL7 FHIR https:\/\/www.hl7.org\/fhir\/index.html (2023)."},{"key":"66_CR17","unstructured":"Venkatesh, K. A., Benjamin, R., Karunakaran, C. & Elango, S. Biosensors and Bioelectronics 247\u2013317 (Elsevier, 2015)."},{"key":"66_CR18","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.esmorw.2025.100112","volume":"7","author":"M Pfeffer","year":"2025","unstructured":"Pfeffer, M., Deneris, M., Shelley, A., Salcuni, P. & Altomare, I. Utility of automated data transfer for cancer clinical trials and considerations for implementation. ESMO Real. World Data Digital Oncol. 7, 100112 (2025).","journal-title":"ESMO Real. World Data Digital Oncol."},{"key":"66_CR19","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2022.514","volume":"7","author":"AC Cheng","year":"2022","unstructured":"Cheng, A. C. et al. Evaluating automated electronic case report form data entry from electronic health records. J. Clin. Transl. Sci. 7, e29 (2022).","journal-title":"J. Clin. Transl. Sci."},{"key":"66_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.seminoncol.2022.01.008","volume":"49","author":"E Hill","year":"2022","unstructured":"Hill, E., Morrison, C. & Kazandjian, D. Daratumumab: a review of current indications and future directions. Semin. Oncol. 49, 48\u201359 (2022).","journal-title":"Semin. Oncol."},{"key":"66_CR21","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","volume":"107","author":"SZ Usmani","year":"2022","unstructured":"Usmani, S. Z. et al. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica 107, 2408\u20132417 (2022).","journal-title":"Haematologica"},{"key":"66_CR22","unstructured":"Janssen Biotech Inc. DARZALEX (daratumumab) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761036s020lbl.pdf (2025)."},{"key":"66_CR23","unstructured":"Janssen Biotech Inc. DARZALEXFASPRO (daratumumab and hyaluronidase\u2011fihj) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761145s000lbl.pdf (2024)."},{"key":"66_CR24","unstructured":"U.S. Food and Drug Administration. Study data standards resources. U.S. Food and Drug Administration https:\/\/www.fda.gov\/industry\/fda-data-standards-advisory-board\/study-data-standards-resources (2025)."},{"key":"66_CR25","unstructured":"U.S. Food and Drug Administration. Use of electronic health record data in clinical investigations guidance for industry. U.S. Food and Drug Administration https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-electronic-health-record-data-clinical-investigations-guidance-industry (2018)."},{"key":"66_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clml.2023.09.004","volume":"24","author":"M Hartley-Brown","year":"2024","unstructured":"Hartley-Brown, M. et al. Creating equitable and inclusive clinical trials for multiple myeloma. Clin. Lymphoma Myeloma Leuk. 24, 32\u201339 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"66_CR27","doi-asserted-by":"crossref","unstructured":"Montano, O. et al. Electronic data capture-study conduct, maintenance and closeout. J. Soc. Clin. Data Manag. 1, 1\u201322 (2021).","DOI":"10.47912\/jscdm.31"},{"key":"66_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-112","volume":"12","author":"EP Tolmie","year":"2011","unstructured":"Tolmie, E. P., Dinnett, E. M., Ronald, E. S. & Gaw, A. Clinical trials: minimising source data queries to streamline endpoint adjudication in a large multi-national trial. Trials 12, 112 (2011).","journal-title":"Trials"},{"key":"66_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1191\/1740774505cn069oa","volume":"2","author":"J Litchfield","year":"2005","unstructured":"Litchfield, J. et al. Is the future for clinical trials internet-based? A cluster randomized clinical trial. Clin. Trials 2, 72\u201379 (2005).","journal-title":"Clin. Trials"},{"key":"66_CR30","doi-asserted-by":"publisher","first-page":"e823","DOI":"10.1200\/JOP.18.00419","volume":"14","author":"AC Chiang","year":"2018","unstructured":"Chiang, A. C. et al. Measuring the impact of academic cancer network development on clinical integration, quality of care, and patient satisfaction. J. Oncol. Pract. 14, e823\u2013e833 (2018).","journal-title":"J. Oncol. Pract."},{"key":"66_CR31","doi-asserted-by":"crossref","unstructured":"Tsai, C. H. et al. Effects of electronic health record implementation and barriers to adoption and use: a scoping review and qualitative analysis of the content. Life 10, 327 (2020).","DOI":"10.3390\/life10120327"},{"key":"66_CR32","unstructured":"Batavia, A. S. et al. Pragmatism in postmarket trials. Friends of Cancer Res. https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Pragmatism-in-Postmarket-Trials-.pdf (2024)."},{"key":"66_CR33","doi-asserted-by":"publisher","first-page":"e2516674","DOI":"10.1001\/jamanetworkopen.2025.16674","volume":"8","author":"DR Rivera","year":"2025","unstructured":"Rivera, D. R. et al. Modernizing research and evidence consensus definitions. JAMA Netw. Open 8, e2516674 (2025).","journal-title":"JAMA Netw. Open"},{"key":"66_CR34","unstructured":"National Comprehensive Cancer Network (NCCN). Multiple myeloma: NCCN guidelines for patients. Natl. Comprehens. Cancer Netw. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/myeloma-patient.pdf (2024)."},{"key":"66_CR35","doi-asserted-by":"publisher","first-page":"e13709","DOI":"10.1200\/JCO.2025.43.16_suppl.e13709","volume":"43","author":"A Afghahi","year":"2025","unstructured":"Afghahi, A. et al. Accrual of historically underrepresented patients with multiple myeloma using centralized screening in a multicenter study. J. Clin. Oncol. 43, e13709\u2013e13709 (2025).","journal-title":"J. Clin. Oncol."},{"key":"66_CR36","unstructured":"Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute. Lead organizations: NCI network trial development and conduct. National Cancer Institute https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development (2025)."},{"key":"66_CR37","unstructured":"U.S. Food and Drug Administration. Postmarketing requirements and commitments: rearchable database. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/scripts\/cder\/pmc\/ (2025)."},{"key":"66_CR38","unstructured":"Society for Clinical Data Management (SCDM). Explore best practices in Clinical Data Management. Society for Clinical Data Management https:\/\/scdm.org\/gcdmp\/ (2025)."},{"key":"66_CR39","unstructured":"TransCelerate BioPharma Inc. Risk\u2011based monitoring methodology. TransCelerate BioPharma https:\/\/www.transceleratebiopharmainc.com\/wp-content\/uploads\/2016\/01\/TransCelerate-RBM-Position-Paper-FINAL-30MAY2013.pdf.pdf (2013)."},{"key":"66_CR40","unstructured":"U.S. Food and Drug Administration. Oversight of clinical investigations \u2014 a risk\u2011based approach to monitoring: guidance for industry. U.S. Food and Drug Administration https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/oversight-clinical-investigations-risk-based-approach-monitoring (2013)."}],"container-title":["npj Health Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00066-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00066-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00066-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:00:54Z","timestamp":1769576454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44401-025-00066-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1038\/s44401-025-00066-9","relation":{},"ISSN":["3005-1959"],"issn-type":[{"value":"3005-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the study period, M.T.G., C.D., A.D., M.K., Y.L., A.R., P.S., N.S., and N.J.M. reported employment with Flatiron Health, Inc. and stock ownership in Roche. D.S., F.B., M.F., L.H., M.R., and A.S.B. reported employment at Johnson & Johnson. R.M.Z. and L.K. had no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}